SG/CALL/BRISTOL-MYERS SQUIBB/62/0.1/17.01.25 | Market Closed - Börse Stuttgart 02:11:52 2024-06-18 EDT | ||
| 0.019 EUR | +5.56% |
|
| Current month | +18.75% | ||
| 1 month | -36.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-18 | 0.019 | +5.56% |
| 24-06-17 | 0.018 | -10.00% |
| 24-06-14 | 0.02 | 0.00% |
| 24-06-13 | 0.02 | -9.09% |
| 24-06-12 | 0.022 | 0.00% |
Delayed Quote Börse Stuttgart
Last update June 18, 2024 at 02:11 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU2VSG |
| ISIN | DE000SU2VSG4 |
| Date issued | 2023-11-28 |
| Strike | 62 $ |
| Maturity | 2025-01-17 (213 Days) |
| Parity | 10 : 1 |
| Emission price | 0.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.23 € |
|---|---|
| Lowest since issue | 0.015 € |
| Spread | 0.01 € |
| Spread % | 38.46% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.81
USD
Average target price
53.19
USD
Spread / Average Target
+30.35%
- Stock Market
- Warrants
- Warrant
